ReidWeyantMerrymanMD

Physician

Dr. Merryman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
450 Brookline Ave
Boston, MA 02215
Phone+1 617-732-6089

Fax+1 617-732-5706

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2019
Brigham and Women's HospitalResidency, Internal Medicine, 2013 - 2016
Harvard Medical SchoolClass of 2013

Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL Start of enrollment: 2021 Jun 04
Active, not recruiting
Phase 2
Roles: Contact, Principal Investigator
Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma Start of enrollment: 2023 Jul 18
Recruiting
Phase 2
Roles: Contact, Sponsor-Investigator, Principal Investigator
Zandelisib + Tazemetostat in R/R Follicular Lymphoma Start of enrollment: 2023 Jan 01
Withdrawn
Phase 1, Phase 2
Roles: Principal Investigator, Contact
Epcoritamab and Rituximab for First-line Follicular Lymphoma Start of enrollment: 2023 Jun 21
Recruiting
Phase 2
Roles: Contact, Principal Investigator, Sponsor-Investigator
Join now to see all

PubMed

62 citations
Autologous Transplant versus Chimeric Antigen Receptor T-cell Therapy for Relapsed DLBCL in Partial Remission.
Mazyar Shadman, Marcelo C. Pasquini, Kwang Woo Ahn, Yue Chen, Cameron J. Turtle
Blood. 2021-09-27
87 citations
Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma
Reid W. Merryman, Philippe Armand, Kyle Wright, Scott J. Rodig
Blood Advances. 2017-12-12
7 citations
Clinical efficacy and safety of chimeric antigen receptor T-cell therapy for mantle cell lymphoma with secondary central nervous system involvement.
Christine E Ryan, Rebecca L Zon, Robert Redd, David C Fisher, Roni Shouval
British Journal of Haematology. 2023-12-01

Abstracts/Posters

Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Le...
Reid W Merryman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

Outcome of Autologous Stem Cell Transplantation Following PD-(L)1 Based Salvage Therapy for Multiply Relapsed Patients with Classic Hodgkin Lymphoma
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019

BEGEV Salvage Regimen Linked to High Complete Remission RatesFebruary 18th, 2020
Treatment with PD-1 Prior to Stem Cell Transplant Is Safe for Hodgkin Lymphoma PatientsDecember 9th, 2019
ASCO 2023: Lymphoma Research Could Change PracticeJune 28th, 2023